{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:28:21Z","timestamp":1770110901947,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12094-020-02315-9","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T19:06:38Z","timestamp":1582571198000},"page":"1778-1785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7204-0800","authenticated-orcid":false,"given":"E.","family":"P\u00e9rez-Ruiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Jim\u00e9nez-Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-A.","family":"Berciano-Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Valdivia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Estalella-Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rodriguez de la Borbolla Artacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Garrido-Siles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Mart\u00ednez-Bautista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Villatoro Roldan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rivas-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Nogales-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"P\u00e9rez-Valderrama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"De la Cruz-Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"issue":"6230","key":"2315_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.aaa4972","volume":"348","author":"WS Garrett","year":"2015","unstructured":"Garrett WS. Cancer and the microbiota. Science. 2015;348(6230):80\u20136.","journal-title":"Science"},{"issue":"7","key":"2315_CR2","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.cell.2015.12.009","volume":"163","author":"J Tan","year":"2015","unstructured":"Tan J. Immunotherapy meets microbiota. Cell. 2015;163(7):1561. https:\/\/doi.org\/10.1016\/j.cell.2015.12.009.","journal-title":"Cell"},{"key":"2315_CR3","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Tomas L, Bondarenko I, et al. Ipilimumab plus dacarbacine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517\u201326.","journal-title":"N Engl J Med"},{"issue":"13","key":"2315_CR4","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMc1509660","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):1270\u20131.","journal-title":"N Engl J Med"},{"issue":"8","key":"2315_CR5","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908\u201318.","journal-title":"Lancet Oncol"},{"key":"2315_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMicm1409470","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:26.","journal-title":"N Engl J Med"},{"key":"2315_CR7","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L. Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"issue":"2","key":"2315_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non\u2013 small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335.","journal-title":"N Engl J Med"},{"issue":"19","key":"2315_CR9","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robison A, et al. Pembrolizumab versus chemotherapy for PD-L1 positive non-small-cell lung cancer. N Engl J Med. 2016;10;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"19","key":"2315_CR10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and necK. N Eng J Med. 2016;375(19):1856\u201367.","journal-title":"N Eng J Med"},{"key":"2315_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1126\/science.aaf2834","volume":"353","author":"C Blank","year":"2016","unstructured":"Blank C, Haanen JB, Ribas A, Schumacher TN. The \u201ccancer immunogram\u201d. Science. 2016;353:658\u201360.","journal-title":"Science"},{"issue":"6161","key":"2315_CR12","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.1240537","volume":"342","author":"S Viaud","year":"2013","unstructured":"Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971\u20136.","journal-title":"Science"},{"issue":"6264","key":"2315_CR13","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"V\u00e9tizou M, Pitt JM, Daill\u00e8re R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079\u201384.","journal-title":"Science"},{"issue":"6264","key":"2315_CR14","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084\u20139.","journal-title":"Science"},{"issue":"6371","key":"2315_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2017","unstructured":"Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epitelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science"},{"key":"2315_CR16","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"L Derosa","year":"2018","unstructured":"Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune check-point inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29:1437\u201344.","journal-title":"Ann Oncol"},{"issue":"6161","key":"2315_CR17","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1126\/science.1240527","volume":"342","author":"N Iida","year":"2013","unstructured":"Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967\u201370.","journal-title":"Science"},{"key":"2315_CR18","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nature25979","volume":"555","author":"L Maier","year":"2018","unstructured":"Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555:623\u20138.","journal-title":"Nature"},{"key":"2315_CR19","doi-asserted-by":"publisher","first-page":"178.e1","DOI":"10.1016\/j.cmi.2015.10.003","volume":"22","author":"MAM Rogers","year":"2016","unstructured":"Rogers MAM, Aronoff DM. The influence of nonsteroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect. 2016;22:178.e1\u20139.","journal-title":"Clin Microbiol Infect"},{"key":"2315_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","volume":"65","author":"MA Jacckson","year":"2016","unstructured":"Jacckson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749\u201356.","journal-title":"Gut"},{"issue":"4","key":"2315_CR21","doi-asserted-by":"publisher","first-page":"e0124599","DOI":"10.1371\/journal.pone.0124599","volume":"10","author":"C Dominianni","year":"2015","unstructured":"Dominianni C, Sinha R, Goedert J, et al. Sex, body mass index, and dietary fiber intake influence the human gut microbiome. PLoS ONE. 2015;10(4):e0124599.","journal-title":"PLoS ONE"},{"key":"2315_CR22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nature15766","volume":"528","author":"K Forslund","year":"2015","unstructured":"Forslund K, Hildebrand F, Nielsen T, et al. Disentangling the effects of type 2 diabetes and metformin on the human gut microbiota. Nature. 2015;528:262\u20136.","journal-title":"Nature"},{"key":"2315_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R, et al. The comensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104\u20138.","journal-title":"Science"},{"issue":"6","key":"2315_CR24","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368\u201379. https:\/\/doi.org\/10.1093\/annonc\/mdx108.","journal-title":"Ann Oncol"},{"key":"2315_CR25","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22:886\u201394.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2315_CR26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","volume":"19","author":"F Conforti","year":"2018","unstructured":"Conforti F, Pala L, Bagnardi V, et al. Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis. Lancet Oncol. 2018;19(6):737\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(18)30261-4Epub 2018 May 16.","journal-title":"Lancet Oncol"},{"key":"2315_CR27","doi-asserted-by":"publisher","first-page":"e9836","DOI":"10.1371\/journal.pone.0009836","volume":"5","author":"HE Jakobsson","year":"2010","unstructured":"Jakobsson HE, Jernberg C, Andersson AF, et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS ONE. 2010;5:e9836.","journal-title":"PLoS ONE"},{"key":"2315_CR28","doi-asserted-by":"crossref","unstructured":"Arbour KC, Mezquita L, Long N, et al. Presented at the ASCO Meeting, Chicago, 2018. J Clin Oncol 36(suppl; abstr 9003).","DOI":"10.1200\/JCO.2018.36.15_suppl.9003"},{"key":"2315_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.004","author":"SC Scott","year":"2018","unstructured":"Scott SC, Pennell NA. Brief report: early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol. 2018. https:\/\/doi.org\/10.1016\/j.jtho.2018.06.004.","journal-title":"J Thorac Oncol"},{"key":"2315_CR30","first-page":"3195","volume":"37","author":"C Kaderbhai","year":"2017","unstructured":"Kaderbhai C, Richard C, Fumet JD, et al. Antibiotic use does not appear to influence response to nivolumab. Anticancer Res. 2017;37:3195\u2013200.","journal-title":"Anticancer Res"},{"key":"2315_CR31","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015;33:3193\u20138.","journal-title":"J Clin Oncol"},{"key":"2315_CR32","doi-asserted-by":"publisher","first-page":"e3952","DOI":"10.7717\/peerj.3952","volume":"5","author":"HH Ko","year":"2017","unstructured":"Ko HH, et al. Statins: antimicrobial resistance breakers or makers? PeerJ. 2017;5:e3952. https:\/\/doi.org\/10.7717\/peerj.3952.","journal-title":"PeerJ"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02315-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-020-02315-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02315-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:54:45Z","timestamp":1614041685000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-020-02315-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2315"],"URL":"https:\/\/doi.org\/10.1007\/s12094-020-02315-9","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"15 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved by the Research Ethics Committee of Costa del Sol Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}